EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

Hyehyun Jeong, Bum Jun Kim, Choong-Kun Lee, Inkeun Park, Dae Young Zang, Hye Jin Choi, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dongwook Oh, Sung-Hoon Moon, Kyu-Pyo Kim und 3 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114194 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Hyehyun Jeong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Irinotecan, Oxaliplatin, Oxonic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Servier Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsIrinotecanOxaliplatinOxonic AcidAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsAdenocarcinomaTegafurHumansMaleFemaleMiddle AgedAgedLiposomesAdultProgression-Free Survival

Stichwörter der Autor:innen

Liposomal irinotecanOxaliplatinPancreatic adenocarcinomaS-1

Substanzen

IrinotecanOxaliplatinOxonic AcidDrug CombinationsS 1 (combination)TegafurLiposomes

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
  • Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: yooc@amc.seoul.kr.

Förderung

  • Servier Institute

Zitieren

APA

Jeong, H., Kim, B. J., Lee, C. K., Park, I., Zang, D. Y., Choi, H. J., Lee, S. S., Park, D. H., Song, T. J., Oh, D., Moon, S. H., Kim, K. P., Wainberg, Z., Ryoo, B. Y., & Yoo, C. (2024). Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114194

Vancouver

Jeong H, Kim BJ, Lee CK, Park I, Zang DY, Choi HJ, et al. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114194

BibTeX
@article{Jeong2024,
  author = {Jeong, Hyehyun and Kim, Bum Jun and Lee, Choong-Kun and Park, Inkeun and Zang, Dae Young and Choi, Hye Jin and Lee, Sang Soo and Park, Do Hyun and Song, Tae Jun and Oh, Dongwook and Moon, Sung-Hoon and Kim, Kyu-Pyo and Wainberg, Zev and Ryoo, Baek-Yeol and Yoo, Changhoon},
  title = {Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114194}
}
Kostenlos starten →